|
1
|
Nur Husna SM, Tan HT, Mohamud R, Dyhl-Polk
A and Wong KK: Inhibitors targeting CDK4/6, PARP and PI3K in breast
cancer. A review. Ther Adv Med Oncol.
10(1758835918808509)2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Dubey AK, Gupta U and Jain S: Breast
cancer statistics and prediction methodology: A systematic review
and analysis. Asian Pacific J Cancer Prev. 16:4237–4245.
2015.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Ayala-Cuellar AP, Cho J and Choi KC:
Toll-like receptors: A pathway alluding to cancer control. J Cell
Physiol. 234:21707–21715. 2019.PubMed/NCBI View Article : Google Scholar
|
|
4
|
McGettrick AF and O'Neill LA: Localisation
and trafficking of Toll-like receptors: An important mode of
regulation. Curr Opin Immunol. 22:20–27. 2010.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Kawai T and Akira S: The role of
pattern-recognition receptors in innate immunity: Update on
Toll-like receptors. Nat Immunol. 11:373–384. 2010.PubMed/NCBI View
Article : Google Scholar
|
|
6
|
Ahmed A, Wang JH and Redmond HP: Silencing
of TLR4 increases tumor progression and lung metastasis in a murine
model of breast cancer. Ann Surg Oncol. 20 (Suppl 3):S389–S396.
2013.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Grimmig T, Moench R, Kreckel J, Haack S,
Rueckert F, Rehder R, Tripathi S, Ribas C, Chandraker A, Germer CT,
et al: Toll like receptor 2, 4, and 9 signaling promotes
autoregulative tumor cell growth and VEGF/PDGF expression in human
pancreatic cancer. Int J Mol Sci. 17(2060)2016.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Al-Harras MF, Houssen ME, Shaker ME, Farag
K, Farouk O, Monir R, El-Mahdy R and Abo-Hashem EM: Polymorphisms
of glutathione S-transferase π 1 and toll-like receptors 2 and 9:
Association with breast cancer susceptibility. Oncol Lett.
11:2182–2188. 2016.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Houssen ME, El-Mahdy RH and Shahin DA:
Serum soluble toll-like receptor 2: A novel biomarker for systemic
lupus erythematosus disease activity and lupus-related
cardiovascular dysfunction. Int J Rheum Dis. 19:685–692.
2016.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Dulay AT, Buhimschi CS, Zhao G, Oliver EA,
Mbele A, Jing S and Buhimschi IA: Soluble TLR2 is present in human
amniotic fluid and modulates the intraamniotic inflammatory
response to infection. J Immunol. 182:7244–7253. 2009.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Henrick BM, Yao XD, Taha AY, German JB and
Rosenthal KL: Insights into soluble Toll-like receptor 2 as a
downregulator of virally induced inflammation. Front Immunol.
7(291)2016.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Langjahr P, Díaz-Jiménez D, De la Fuente
M, Rubio E, Golenbock D, Bronfman FC, Quera R, González MJ and
Hermoso MA: Metalloproteinase-dependent TLR2 ectodomain shedding is
involved in soluble toll-like receptor 2 (sTLR2) production. PLoS
One. 9(e104624)2014.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Ten Oever J, Kox M, van de Veerdonk FL,
Mothapo KM, Slavcovici A, Jansen TL, Tweehuysen L,
Giamarellos-Bourboulis EJ, Schneeberger PM, Wever PC, et al: The
discriminative capacity of soluble Toll-like receptor (sTLR)2 and
sTLR4 in inflammatory diseases. BMC Immunol. 15(55)2014.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Domenis R, Cifù A, Marinò D, Fabris M,
Niazi KR, Soon-Shiong P and Curcio F: Toll-like receptor-4
activation boosts the immunosuppressive properties of tumor
cells-derived exosomes. Sci Rep. 9(8457)2019.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Bhattacharya D and Yusuf N: Expression of
toll-like receptors on breast tumors: Taking a toll on tumor
microenvironment. Int J Breast Cancer. 2012(716564)2012.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Yang CX, Li CY and Feng W: Toll-like
receptor 4 genetic variants and prognosis of breast cancer. Tissue
Antigens. 81:221–226. 2013.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Yusuf N: Toll-like receptors and breast
cancer. Front Immunol. 5(84)2014.
|
|
18
|
Hossain MJ, Morandi E, Tanasescu R,
Frakich N, Caldano M, Onion D, Faraj TA, Erridge C and Gran B: The
soluble form of toll-like receptor 2 is elevated in serum of
multiple sclerosis patients: A novel potential disease biomarker.
Front Immunol. 9(457)2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Holst B, Szakmany T, Raby AC, Hamlyn V,
Durno K, Hall JE and Labéta MO: Soluble Toll-like receptor 2 is a
biomarker for sepsis in critically ill patients with multi-organ
failure within 12 h of ICU admission. Intensive Care Med Exp.
5(2)2017.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Liew FY, Xu D, Brint EK and O'Neill LA:
Negative regulation of toll-like receptor-mediated immune
responses. Nat Rev Immunol. 5:446–458. 2005.PubMed/NCBI View
Article : Google Scholar
|
|
21
|
Wei F, Yang F, Li J, Zheng Y, Yu W, Yang L
and Ren X: Soluble Toll-like receptor 4 is a potential serum
biomarker in non-small cell lung cancer. Oncotarget. 7:40106–40114.
2016.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Huang B, Zhao J, Unkeless JC, Feng ZH and
Xiong H: TLR signaling by tumor and immune cells: A double-edged
sword. Oncogene. 27:218–224. 2008.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Huang B, Zhao J, Li H, He KL, Chen Y, Chen
SH, Mayer L, Unkeless JC and Xiong H: Toll-like receptors on tumor
cells facilitate evasion of immune surveillance. Cancer Res.
65:5009–5014. 2005.PubMed/NCBI View Article : Google Scholar
|
